Introduction {#s1}
============

Despite major therapeutic advances, there is no cure for rheumatoid arthritis (RA) and only a small proportion of patients achieve drug-free remission, which is often transient.[@R1] For the remainder, the need for chronic medications with associated side effects, sometimes serious, impacts on overall quality of life. The ideal management of RA is a therapy that returns the immune system to a state of self-tolerance, reversing autoimmunity without requiring long-term treatment.

Dendritic cells (DCs) orchestrate immune responses, by ingesting and presenting antigens to T cells.[@R2] [@R3] In health they direct immune attacks against pathogens and tumours and, in a distinct state of differentiation, play an important role in maintaining self-tolerance.[@R4] [@R5] In contrast, in autoimmunity DCs drive activation and differentiation of autoreactive effector T cells.[@R6] If this inappropriate activation could be reversed and immune regulation restored, self-tolerance should re-emerge.

Over the past 10 years, we have developed a method to differentiate human tolerogenic DC (tolDC) from the blood of healthy individuals and patients with inflammatory arthritis.[@R7] Unlike conventional mature DCs, which produce interleukin (IL)-12p70 and other proinflammatory cytokines, tolDC produce no IL-12p70 but high levels of IL-10. They deviate naïve T cells towards an IL-10-producing phenotype and induce hyporesponsiveness in memory T cells. Importantly, in mixed cultures they dominate mature, proinflammatory DCs and downregulate T-cell activation. Their phenotype is stable in the presence of proinflammatory stimuli. Equivalent murine tolDC switch off collagen-induced arthritis (CIA), with immune deviation from IL-17 to IL-10 production by CD4+ T cells and a reduction in type II collagen-specific T-cell responses.[@R11] While our data implicate IL-10 as a key anti-inflammatory cytokine, it can also boost B-cell responses with pro-immune effects.[@R12]

We now report the results of a Phase I trial of autologous tolDC in patients with rheumatoid and inflammatory arthritis. This is only the second reported trial of tolDC in inflammatory arthritis[@R13] and the first to use an intra-articular (IA) route of administration, chosen to optimise the detection and management of potential AEs.

Methods {#s2}
=======

TolDC manufacture {#s2a}
-----------------

We previously reported our method for manufacturing therapeutic grade tolDC investigational medical product (IMP).[@R9] Our full good manufacturing practice (GMP) protocol is provided in the online [supplementary methods](#SM1){ref-type="supplementary-material"}. TolDC were loaded with autologous synovial fluid (SF) as a source of relevant autoantigens,[@R14] enabling the treatment of both patients with seropositive RA and patients with seronegative RA, as well as other arthritides. Prior to administration, tolDC satisfied all quality control (QC) release criteria ([table 1](#ANNRHEUMDIS2015208456TB1){ref-type="table"}).

###### 

Summary of QC release criteria data

                       Purity   Phenotype   Functionality                                        
  ---- ---------- ---- -------- ----------- --------------- ------ ------ -------- ------ ------ ------
  1    1×10^6^    88   100      100         58              462    1434   2364     \<50   Pass   Pass
  2    Placebo    --   --       --          --              --     --     --       --     --     --
  3    1×10^6^    88   99.9     100         41              773    1188   3373     \<50   Pass   Pass
  4    1×10^6^    90   100      100         109             356    758    10 510   \<50   Pass   Pass
  5    3×10^6^    90   99.9     100         173             384    2085   2295     \<50   Pass   Pass
  6    Placebo    --   --       --          --              --     --     --       --     --     --
  7    3×10^6^    96   100      99.9        73              390    2921   5164     \<50   Pass   Pass
  8    3×10^6^    96   100      100         61              1878   251    1331     \<50   Pass   Fail
  9    3×10^6^    71   100      100         70              772    926    2040     \<50   Pass   Pass
  10   10×10^6^   80   100      100         83              264    4276   2425     \<50   Pass   Pass
  11   Placebo    --   --       --          --              --     --     --       --     --     --
  12   10×10^6^   79   100      100         62              464    1704   4679     \<50   Pass   Pass
  13   10×10^6^   95   99.8     100         135             320    1473   1607     \<50   Pass   Pass

\*Viability was determined using trypan blue exclusion and expressed as percentage of total cells. To pass quality control (QC) viability had to be \>70%.

†Sterility was assessed by BacT/Alert and fungal screen on day 0, day 3 and final product (day 7). To pass QC, the product had to pass sterility screening with no organisms detected.

‡CD11c and human leucocyte antigen---antigen D-related (HLA-DR) expression determined using flow cytometry and expressed as a percentage of viable cells. To pass QC, the percentage of positive cells had to be \>90% for both markers.

§CD83 expression determined using flow cytometry and expressed as a median fluorescence intensity (MFI) of viable cells. To pass QC, CD83 MFI had to be \<350.

¶CD86 expression determined using flow cytometry and expressed as a MFI of viable cells. To pass QC, CD86 MFI had to be \<1500.

\*\*Toll-like receptor (TLR)2 expression determined using flow cytometry and expressed as a MFI of viable cells. For information only. Positive result=TLR2 MFI \>200.

††Interleukin (IL)-10 levels in supernatant from the 7 days culture were determined by ELISA. To pass QC, IL-10 levels had to be \>1000 pg/mL.

‡‡IL-12 levels in supernatant from the 7 days culture were determined by ELISA. To pass QC, IL-12 levels had to be \<50 pg/mL.
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Participants {#s2b}
------------

Participants, aged 18 or over, had inflammatory arthritis of at least 6 months\' duration, including an inflamed knee joint with an effusion and at least 30 min early morning stiffness. They had failed at least one disease-modifying antirheumatic drug (DMARD), including current therapy. TolDC was added to stable DMARD and anti-inflammatory therapies. Intramuscular glucocorticoids and IA injections of the target knee were not permitted for 6 weeks prior to baseline. Standard exclusion criteria were applied (see online [supplementary table](#SM2){ref-type="supplementary-material"} S1).

10.1136/annrheumdis-2015-208456.supp2

Study design {#s2c}
------------

This was an unblinded, randomised, controlled, dose escalation Phase I trial of IA tolDC administered into an inflamed knee joint (the target knee). The trial protocol, available at <http://clinicaltrials.gov/ct2/show/NCT01352858>, was approved by the Medicines and Healthcare Products Regulatory Agency and by the National Research Ethics Service Committee North East (Sunderland) (EudraCT number: 2011-001582-41). The trial was conducted according to the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Good Clinical Practice (ICH GCP) and the Declaration of Helsinki. There were three dosing cohorts of 1×10^6^, 3×10^6^ and 10×10^6^ viable tolDC administered via a single arthroscopic injection following saline irrigation. Each cohort comprised four participants, randomly allocated to tolDC (n=3) or control intervention of target knee arthroscopic saline irrigation only (n=1). The decision to dose escalate between cohorts was decided by an independent data-monitoring committee based on safety and tolerability data, recorded 5 days after treatment of the last participant in each cohort.

The study design is outlined in [figure 1](#ANNRHEUMDIS2015208456F1){ref-type="fig"}. Following informed consent on day −14, an infectious disease screen was performed and SF aspirated for use during tolDC manufacture. Participants returned on day −7 for leucapheresis. At the baseline visit (day 0), the target joint was arthroscopically irrigated followed by tolDC administration. IA administration was chosen to provide an early and robust signal of disease deterioration and the opportunity for joint irrigation under those circumstances.

![Overview showing tolerogenic dendritic cells (tolDC) treatment protocol. Following informed consent on day −14, an infectious disease screen was performed and synovial fluid (SF) aspirated under ultrasound guidance for use during tolDC manufacture. Participants returned 7 days later (day −7) for leucapheresis, their leucapheresis product being transferred to the good manufacturing practice facility for initiation of tolDC manufacture. After a further 7 days participants returned (day 0, baseline visit) and, following a clinical assessment and ultrasound assessment of the target knee, underwent fibre-optic arthroscopy. The target knee joint was irrigated with 1 L of normal saline, following which tolDC were administered arthroscopically. On days 7 and 14 participants returned for safety assessments. The day 14 visit also entailed an arthroscopic assessment of the target knee. If the participant remained symptomatic and/or the knee remained inflamed an arthroscopic intra-articular glucocorticoid injection was administered. The final study visit on day 91 was identical to the day +14 visit.](annrheumdis-2015-208456f01){#ANNRHEUMDIS2015208456F1}

Primary outcome {#s2d}
---------------

The primary objective of Autologous Tolerogenic Dendritic Cells for Rheumatoid and Inflammatory Arthritis (AuToDeCRA) was to assess safety of the intervention. Participants were questioned about symptomatic deterioration by telephone on days 1--5, with particular focus on the target knee. If deterioration was reported on two successive days, participants were assessed in person. If deterioration was confirmed, a further arthroscopic examination was performed with irrigation and IA glucocorticoid if indicated. If infection was suspected, this was managed appropriately. Knee assessment tools standardised subjective and objective assessments (see online [supplementary figure](#SM2){ref-type="supplementary-material"}s S1 and S2). Routine safety assessments took place on days 7 and 14. The latter included a further arthroscopic examination and, if synovitis persisted, an arthroscopic IA glucocorticoid injection was administered. The final study visit on day 91 was identical to day 14, except arthroscopy was only indicated if patients had not previously received IA glucocorticoid during the study.

The primary outcome was the proportion of participants experiencing a target knee flare within 5 days of tolDC administration and, additionally, the proportion experiencing serious AEs (SAEs) and AEs throughout the trial. Although tolDC were stable in vitro, a significant concern was their potential to become activated in an inflamed environment---our experiments in murine CIA demonstrated worsening of joint inflammation when antigen-loaded mature DCs were administered.[@R11] Knee flares beyond 5 days were deemed more likely to represent inflammation returning post-irrigation, whereas, if tolDC were efficacious, we predicted prolonged symptomatic benefit.

Secondary and exploratory outcomes {#s2e}
----------------------------------

Secondary objectives were to assess feasibility and tolerability. Feasibility was defined by the proportion of participants entering the study from whom tolDC could be prepared (the success rate of tolDC manufacture). Tolerability was scored as the proportion of participants who rated the study and its components as partly or completely acceptable, assessed via a questionnaire administered at the final study visit (see online [supplementary figure](#SM1){ref-type="supplementary-material"} S3).

Exploratory objectives included assessment of the potential effects of tolDC on local and systemic disease activities. Exploratory outcomes included arthroscopic assessment of target knee synovitis (days 0 and +14); disease activity score (DAS)28 and Health Assessment Questionnaire (HAQ) at each study visit; peripheral blood T-cell phenotype assessed by intracellular cytokine staining and peripheral blood cytokine levels (days 0, 14 and 91, see online [supplementary methods](#SM1){ref-type="supplementary-material"}). Arthroscopy was performed by an unblinded investigator using a published method.[@R17]

Statistics {#s2f}
----------

This Phase I trial was not powered for comparative hypothesis testing and basic descriptive statistics are used to summarise outcome data, demographic and operational information.

Results {#s3}
=======

Participants {#s3a}
------------

Sixteen participants were screened. SF could not be obtained from three and the cell product did not meet release criteria in participant 8 (see below). Of the remaining 12 participants, 6 had seropositive RA, 1 had seronegative RA, 3 had psoriatic arthritis and 2 had undifferentiated seronegative arthritis ([table 2](#ANNRHEUMDIS2015208456TB2){ref-type="table"}). The 10×10^6^ tolDC cohort contained only one patient with RA, whereas the lower dose cohorts contained three each. Disease duration ranged from 2 to 43 years and DAS28 ranged from 1.4 to 6.0. Background DMARD therapy ranged from nil to biological therapy.

###### 

Participant demographics, current and prior treatment and experimental cohort

  Participant number   Age (years)   Diagnosis                                 Disease duration (years)   DAS28 at baseline   Background DMARD treatment   Prior treatments                          tolDC treatment
  -------------------- ------------- ----------------------------------------- -------------------------- ------------------- ---------------------------- ----------------------------------------- -----------------
  1                    75            Seropositive RA                           43                         2.6\*               PEN                          Nil                                       1×10^6^
  2                    59            Seropositive RA                           19                         4.5                 MTX s/c                      SSZ, po MTX                               Washout
  3                    53            Seropositive RA                           14                         6.0                 ADA                          PEN, gold, SSZ, MTX, LEF, ETA, ADA, RTX   1×10^6^
  4                    56            Psoriatic arthritis                       6                          2.6                 MTX, LEF                     Nil                                       1×10^6^
  5                    41            Undifferentiated seronegative arthritis   3                          3.5\*               MTX                          SSZ                                       3×10^6^
  6                    63            Seropositive RA                           31                         5.1                 MTX, ETA                     MTX, LEF, gold, SSZ, PEN                  Washout
  7                    35            Seropositive RA                           3                          4.4                 MTX, SSZ, HCQ                Nil                                       3×10^6^
  8†                   47            Seronegative arthritis                    1                          1.4                 MTX                          SSZ                                       3×10^6^†
  9                    60            Seronegative RA                           14                         5.2                 MTX, HCQ                     Nil                                       3×10^6^
  10                   77            Psoriatic arthritis                       3                          4.4\*               MTX, SSZ                     Nil                                       10×10^6^
  11                   65            Seropositive RA                           2                          4.5                 MTX, SSZ, HCQ                Nil                                       Washout
  12                   57            Undifferentiated seronegative arthritis   4                          2.3                 MTX                          Nil                                       10×10^6^
  13                   45            Psoriatic arthritis                       18                         2.2                 Nil                          MTX, SSZ                                  10×10^6^

\*Screening DAS28 values.

†Cells failed release criteria.

ADA, adalimumab; DMARD, disease-modifying antirheumatic drug; ETA, etanercept; HCQ, hydroxychloroquine; LEF, leflunomide; MTX, methotrexate; PEN, penicillamine; po, oral administration; RA, rheumatoid arthritis; RTX, rituximab; s/c, subcutaneous administration; SSZ, sulfasalazine; tolDC, tolerogenic dendritic cells.

Product characteristics {#s3b}
-----------------------

[Table 1](#ANNRHEUMDIS2015208456TB1){ref-type="table"} provides the QC release criteria for tolDC, encompassing viability, sterility, phenotype and function. The IMP generated from cells of participant 8 had higher cell surface CD86 expression than specified in our release criteria and therefore could not be released as part of the clinical trial. All other release criteria were met and, following informed discussion, the participant elected to receive the product but their data are reported separately. Toll-like receptor 2 is upregulated during tolDC differentiation and, while recorded in [table 1](#ANNRHEUMDIS2015208456TB1){ref-type="table"}, did not constitute a release criterion. Online [supplementary figure](#SM2){ref-type="supplementary-material"} S4 exemplifies flow cytometry QC data.

Primary outcome and AEs {#s3c}
-----------------------

No participants developed worsening symptoms in the target knee during days 1--5. There were two SAEs, both in participant 3 with highly active, refractory RA ([table 3](#ANNRHEUMDIS2015208456TB3){ref-type="table"}). A generalised RA flare occurred on day 70, requiring hospitalisation. Adalimumab was switched to tocilizumab but the participant was re-admitted 15 days later with pneumonia requiring IV antibiotics. Both events were felt unlikely to be related to tolDC.

###### 

Adverse events and serious adverse events (SAEs)

  Study number   Cohort           Adverse event                                               Grade       Day   Action                                  Relationship to treatment   Relationship to procedure
  -------------- ---------------- ----------------------------------------------------------- ----------- ----- --------------------------------------- --------------------------- ----------------------------------------
  1              1×10^6^ tolDC    Discomfort right heel                                       Mild        0     Nil                                     Unrelated                   Probable (secondary to immobilisation)
  1              1×10^6^ tolDC    Redness right heel                                          Mild        0     Nil                                     Unrelated                   Probable (secondary to immobilisation)
  1              1×10^6^ tolDC    Bruising below knee                                         Mild        1     Nil                                     Unrelated                   Related to arthroscopy
  1              1×10^6^ tolDC    Target knee synovitis                                       Moderate    10    Aspiration d10, IA glucocorticoid d14   Possible                    Unrelated
  1              1×10^6^ tolDC    Wound infection target knee                                 Mild        31    Oral flucloxacillin                     Unlikely                    Related to arthroscopy
  2              Control          Leg cramps                                                  Mild        ≈14   Quinine sulfate                         Unrelated                   Unlikely
  3              1×10^6^ tolDC    Iron deficiency anaemia                                     Moderate    −14   Ferrous sulfate                         Unrelated                   Unrelated
  3              1×10^6^ tolDC    Citrate Toxicity                                            Mild        −7    Nil                                     Unrelated                   Related to leucapheresis
  3              1×10^6^ tolDC    Increased target knee pain                                  Moderate    0     Analgesia                               Unlikely                    Related to arthroscopy
  3              1×10^6^ tolDC    Fatigue                                                     Mild        1     Nil                                     Unlikely                    Possible
  3              1×10^6^ tolDC    General RA flare                                            Moderate    9     IM glucocorticoid                       Possible                    Unrelated
  3              1×10^6^ tolDC    General RA flare                                            N/A (SAE)   70    Hospitalised, commenced tocilizumab     Unlikely                    Unrelated
  3              1×10^6^ tolDC    Pneumonia                                                   N/A (SAE)   85    Hospitalised, antibiotics               Unlikely                    Unrelated
  4              1×10^6^ tolDC    Increased stiffness of target knee                          Moderate    1     Nil                                     Unlikely                    Possible
  4              1×10^6^ tolDC    New patch of psoriasis on forearm                           Mild        6     Topical steroid/calcipitriol            Possible                    Unrelated
  4              1×10^6^ tolDC    Increased pain both knees                                   Mild        6     Nil                                     Possible                    Unrelated
  5              3×10^6^ tolDC    Flare IA                                                    Mild        −7    Nil                                     Unrelated                   Unrelated
  5              3×10^6^ tolDC    Rhinorrhoea                                                 Mild        3     Nil                                     Possible                    Unrelated
  5              3×10^6^ tolDC    Target knee synovitis                                       Moderate    10    Aspirated, naproxen dose ↑              Possible                    Unrelated
  5              3×10^6^ tolDC    Eczema right elbow                                          Mild        57    Topical hydrocortisone                  Unlikely                    Unrelated
  6              Control          Rash right forearm                                          Mild        −7    Nil                                     Unrelated                   Unrelated
  6              Control          Upper respiratory tract infection                           Mild        44    Oral amoxicillin                        Unrelated                   Unrelated
  7              3×10^6^ tolDC    Increased stiffness in target knee                          Mild        9     Ibuprofen                               Possible                    Unrelated
  8\*                             Wound infection                                             Mild        2     Oral flucloxacillin                     Unrelated                   Related to arthroscopy
  9              3×10^6^ tolDC    Non-target knee synovitis                                   Moderate    0     Ibuprofen                               Unrelated                   Unrelated
  9              3×10^6^ tolDC    Fatigue                                                     Mild        4     Nil                                     Possible                    Unrelated
  9              3×10^6^ tolDC    Elevated C reactive protein and bilateral knee synovitits   Moderate    7     IA glucocorticoid                       Possible                    Unrelated
  9              3×10^6^ tolDC    Fatigue                                                     Mild        10    Nil                                     Possible                    Unrelated
  9              3×10^6^ tolDC    Fluid leak from target knee wound                           Mild        21    Oral flucloxacillin                     Unrelated                   Related to arthroscopy
  10             10×10^6^ tolDC   Increased target knee pain after long walk                  Mild        6     Nil                                     Possible                    Unrelated
  10             10×10^6^ tolDC   Worsening psoriasis bottom of feet                          Mild        55    Topical calcipitriol                    Possible                    Unrelated
  10             10×10^6^ tolDC   Arthralgia due to osteoarthritis                            Mild        ≈60   Nil                                     Unrelated                   Unrelated
  11             Control          Iron deficiency anaemia                                     Moderate    ≈11   Ferrous gluconate                       Unlikely                    Possible
  11             Control          Rhinorrhoea                                                 Mild        13    Nil                                     Unrelated                   Unrelated
  13             10×10^6^ tolDC   Vasovagal episode                                           Mild        0     Nil                                     Unrelated                   Related to arthroscopy
  13             10×10^6^ tolDC   Upper respiratory tract infection                           Mild        11    Paracetamol                             Possible                    Unrelated
  13             10×10^6^ tolDC   General stiffness and discomfort                            Mild        23    Nil                                     Possible                    Unrelated
  13             10×10^6^ tolDC   Folliculitis                                                Mild        28    Nil                                     Possible                    Unrelated
  13             10×10^6^ tolDC   Swelling non-target knee with effusion                      Mild        84    IA glucocorticoid                       Unlikely                    Unrelated

\*Cells from study number (participant) 8 did not meet QC release criteria, see table 1.

IA, intra-articular; IM, intra-muscular; N/A, not applicable; RA, rheumatoid arthritis; tolDC, tolerogenic dendritic cells.

37 AEs were recorded ([table 3](#ANNRHEUMDIS2015208456TB3){ref-type="table"}). 15 were felt possibly related to therapy, largely because of their timing. Despite the lack of protocol-defined target knee flares, there were three episodes of target knee synovitis requiring treatment, noted on days 7 (participant 9) and 10 (participants 1 and 5). Participant 9 also had contralateral knee synovitis, present since baseline. In addition participant 3, who was hospitalised with an RA flare on day 70, also suffered a flare on day 9. Two of these AEs occurred in the 1×10^6^ tolDC and two in the 3×10^6^ tolDC cohort. Participant 7 reported increased target knee stiffness on day 9 and participant 13 reported generalised stiffness and discomfort on day 23 but, clinically, these were not disease flares. Participant 13 subsequently developed non-target knee synovitis on day 84. Two episodes of rhinorrhoea (3×10^6^ tolDC and control), two episodes of upper respiratory tract infection (10×10^6^ tolDC and control) and folliculitis (10×10^6^ tolDC) were the only infectious AEs, excluding wound infections (see below). Two participants with psoriatic arthritis reported minor worsening of psoriasis on days 6 and 62. There were two reports of self-resolving knee pain, one provoked by exercise.

Twelve AEs were possibly, probably or definitely attributable to procedures, including two wound infections (one in participant 8 whose product failed QC) and a fluid leak, an episode of citrate toxicity related to leucapheresis and a vasovagal episode related to arthroscopy. Self-resolving AEs occurring within 24 h of tolDC administration, such as fatigue or target knee pain or stiffness, were attributed to the procedure rather than to tolDC. All AEs were assessed as mild or moderate with no evidence of a dose--response relationship. In particular knee, or systemic disease, flares only occurred in lower dose cohorts, apart from a late (day 84) non-target knee flare in participant 13.

Secondary outcomes---feasibility and participant acceptability {#s3d}
--------------------------------------------------------------

TolDC that met release criteria were manufactured from 9 of 10 production runs (see above). Participant acceptability was high ([table 4](#ANNRHEUMDIS2015208456TB4){ref-type="table"}). About 91% of participants rated the study overall as acceptable. Equivalent percentages were 88%, 75%, 91% and 64% for leucapheresis, knee aspiration, ultrasound and arthroscopy. About 91% found participation convenient and 90% would participate again.

###### 

Participant acceptability scores

  Question                                  N    1\. Totally disagree   2\. Partly Disagree   3\. Neither agree nor disagree   4\. Partially agree   5\. Totally agree   Per cent answer 4 or 5   Per cent answer 5
  ----------------------------------------- ---- ---------------------- --------------------- -------------------------------- --------------------- ------------------- ------------------------ -------------------
  Taking part in the study was convenient   11   1                      0                     0                                2                     8                   91                       73
  The overall study was acceptable          11   1                      0                     0                                1                     9                   91                       82
  I would take part in the study again      10   1                      0                     0                                2                     7                   90                       70
  Knee joint aspiration was acceptable      8    1                      0                     1                                1                     5                   75                       63
  Leucapheresis was acceptable              8    1                      0                     0                                1                     6                   88                       75
  Knee ultrasound was acceptable            11   1                      0                     0                                1                     9                   91                       82
  Knee arthroscopy was acceptable           11   1                      1                     2                                3                     4                   64                       36

Potential efficacy {#s3e}
------------------

[Figure 2](#ANNRHEUMDIS2015208456F2){ref-type="fig"} illustrates the exploratory outcome of arthroscopic assessment of target knee synovitis on day 0 and day 14. A 0--4 scale was used to estimate synovial hypertrophy, vascularity and synovitis. One participant in the 10×10^6^ tolDC cohort declined day 14 arthroscopy. There was no evidence for change in synovial hypertrophy with tolDC, improvement being noted in only one control participant. Two of three participants receiving 3×10^6^ tolDC and one of two assessable participants receiving 10×10^6^ tolDC demonstrated improvement in vascularity on day 14, whereas no improvement was seen in six participants receiving 1×10^6^ tolDC or control intervention. Synovitis improved in one of three participants in each of the 1×10^6^ and 3×10^6^ tolDC cohorts and in both assessable patients in the 10×10^6^ tolDC cohorts, but zero of three controls. Notably there was no worsening of any arthroscopic parameter at day 14 in the 10×10^6^ tolDC cohort. Furthermore, although most patients did not report target knee flares, 10 participants received IA glucocorticoid at day 14 for arthroscopically evident synovitis. The exceptions were two participants in the 10×10^6^ tolDC cohort, one of whom declined day 14 arthroscopy due to symptom resolution (participant 10) and the other, participant 12, had near complete resolution of synovitis at arthroscopy. Both remained asymptomatic and declined day 91 arthroscopies. Interestingly, participant 8, whose cells failed release criteria, also did not require IA glucocorticoid on day 14; day 91 arthroscopy revealed stable hypertrophy and vascularity but mild worsening of synovitis. There was no consistent trend in DAS28 or HAQ scores across the dosing cohorts (data not shown), nor in peripheral blood T-cell phenotype or serum cytokine levels (see online [supplementary figure](#SM2){ref-type="supplementary-material"}s S5 and S6).

![Arthroscopic synovitis scores are presented. Hypertrophy, vascularity and synovitis were scored on a 0--4 scale (17). (A) Individual patient data are illustrated for days 0 and 14 (one patient in the 10×10^6^ tolerogenic dendritic cells (tolDC) cohort declined day 14 arthroscopy). (B) Fold change is shown in hypertrophy, vascularity and synovitis scores compared with day 0. Data are plotted as the mean value for each cohort.](annrheumdis-2015-208456f02){#ANNRHEUMDIS2015208456F2}

Discussion {#s4}
==========

The primary purpose of this unblinded Phase I trial was to assess the safety of autologous tolDC therapy. We consequently designed our trial to provide a robust signal of worsening synovitis and a means to address this if it occurred. IA administration served both purposes: a tolDC-induced flare should have caused a rapid and significant increase in target knee synovitis, in which case the joint could be irrigated and treated with local glucocorticoid. We estimated 5 days as a likely time course, because pathogenic T cells are enriched in an inflamed joint[@R18] and could potentially be activated if tolDC were unstable. No flare occurred within this timeframe although four episodes of target knee or systemic synovitis were recorded between days 7 and 10, in participants receiving 1×10^6^ or 3×10^6^ tolDC. Furthermore, at day 14, local glucocorticoid was administered for arthroscopic synovitis in all patients in the 1×10^6^ and 3×10^6^ tolDC cohorts as well as all three controls. In contrast, two of three participants who received 10×10^6^ tolDC did not require local glucocorticoid throughout the study. Therefore, we cannot state unequivocally that tolDC therapy is safe but it is possible that most participants in this small trial received a subtherapeutic dose of tolDC, the 'flares' and arthroscopic synovitis on day 14 reflecting the natural history of synovitis following joint irrigation.

Participant 3, with refractory RA, suffered two SAEs. The first was a disease flare 10 weeks after tolDC treatment. Adalimumab was switched to tocilizumab but pneumonia developed 14 days later. Neither SAE was felt related to tolDC therapy. This participant also suffered a generalised RA flare on day +9, suggesting they had unstable disease. Skin psoriasis was reported as stable at baseline in patients 4 and 10 and, therefore, minor worsening on days 6 and 62 was deemed potentially attributable to tolDC. The only infections recorded were two wound infections related to arthroscopy ports, two upper respiratory tract infections, two episodes of rhinorrhoea and one of folliculitis. All AEs were categorised as mild or moderate, with no dose--response.

Each tolDC product was subject to QC assessment. Purity, surface phenotype and cytokine production were based on characteristics which we have consistently observed to distinguish tolDC from mature DCs. Because of a necessarily narrow time window following completion of manufacture (approximately 3 h), some data were unavailable at the time of administration. Sterility of the administered product, and cytokine production, only became available later (secondary release criteria). Only one product failed to meet primary release criteria, with CD86 expression modestly above the specified limit. Despite the intensive nature of the protocol, 91% of participants rated their experience as acceptable. Arthroscopy itself was rated least favourably, but most participants totally (4/11) or partially (3/11) rated it as acceptable. About 90% would participate again in a similar study.

On the basis of this small, unblinded, Phase I trial we believe that tolDC therapy is safe and worthy of further investigation. This conclusion is based on the absence of protocol-defined target knee flares and on anecdotal evidence of improvement in participants in the highest dose cohort. There were three knee flares recorded 7--10 days post-tolDC administration but these occurred in the lower dose cohorts and are therefore more likely to reflect the natural history of knee synovitis following joint irrigation. Because there were no prior reports of tolDC administration in participants with inflammatory arthritis, our dosing regimen was based on cancer strategies. In those scenarios, however, mature DCs boost an anti-tumour immune response and extrapolation to tolerance induction is not necessarily appropriate. Indeed, extrapolation from our prior work in CIA would have predicted a higher therapeutic dose. In contrast, in a recently published study in RA, 1×10^6^ and 5×10^6^ autologous modified DCs loaded with citrullinated peptide antigens demonstrated possible clinical benefit and biological activity.[@R13] However, those cells were manufactured by exposure to a nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) inhibitor and were administered intradermally. The IA route, while providing a robust safety read-out, may provide a more challenging environment for tolDC to demonstrate efficacy. An important additional question is whether the IA route could provide a systemic effect. No such effect was evident in our study, either clinically or in terms of T-cell modulation. We are currently planning an extension to AuToDeCRA in which 10×10^6^ tolDC will be radiolabelled before IA administration. This will address whether IA tolDC migrate to local lymph nodes, where they could modulate the systemic immune response.

Our protocol enabled treatment of a range of arthritides. Seven participants had RA, three had psoriatic arthritis and two had undifferentiated seronegative arthritis. Although psoriatic arthritis may be considered a disease of the innate immune system, there remains considerable support for an autoimmune aetiology.[@R21] Furthermore, some tolDC safety concerns (eg, sterility, potential for proinflammatory cytokine release) are independent of the disease being treated. In fact the patients with possible sustained responses had psoriatic arthritis and seronegative undifferentiated arthritis. This may reflect diagnostic imbalance across dosing cohorts, the only RA patient in the 10×10^6^ tolDC cohort receiving control intervention. Nonetheless, these data emphasise the safety and potential utility of tolDC across a range of arthritides with differing aetiology. Notably, targeting IL-17 is effective in psoriatic arthritis and tolDC deviate T-cells in CIA from IL-17 to IL-10 production.[@R11]

While ideal for assessing safety, and well-tolerated by participants, IA tolDC administration is an invasive intervention. TolDC have also been administered intradermally in juvenile type 1 diabetes[@R22] and intraperitoneally in Crohn\'s disease.[@R23] Intradermal administration provides a more convenient route of administration particularly if, as in our preclinical studies, multiple tolDC administrations are ultimately required for robust efficacy.[@R11] Similarly, loading tolDC with autologous SF broadens the target population and obviates the need for tissue-typing, which is generally necessary when loading tolDC with autoantigenic peptides. Nonetheless, joint aspiration is a further invasive procedure and three participants were excluded because SF could not be obtained. Thus, there are advantages and disadvantages to our current protocol. Nonetheless, we believe that AuToDeCRA has defined a safe, and potentially active, dose of tolDC on which to base future work.
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